Display options
Cite
Zhao W, Liu L, Wang Y, et al. Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease. Exp Ther Med. 2015;11(1):183-190doi: 10.3892/etm.2015.2846.
Zhao, W., Liu, L., Wang, Y., Mao, T., & Li, J. (2016). Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease. Experimental and therapeutic medicine, 11(1), 183-190. https://doi.org/10.3892/etm.2015.2846
Zhao, Weihan, et al. "Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease." Experimental and therapeutic medicine vol. 11,1 (2016): 183-190. doi: https://doi.org/10.3892/etm.2015.2846
Zhao W, Liu L, Wang Y, Mao T, Li J. Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease. Exp Ther Med. 2016 Jan;11(1):183-190. doi: 10.3892/etm.2015.2846. Epub 2015 Nov 09. PMID: 26889237; PMCID: PMC4726904.
Copy Download .nbib Format: NLM
Share it on

Exp Ther Med. 2016 Jan;11(1):183-190. doi: 10.3892/etm.2015.2846. Epub 2015 Nov 09.

Effects of a combination of puerarin, baicalin and berberine on the expression of proliferator-activated receptor-γ and insulin receptor in a rat model of nonalcoholic fatty liver disease.

Experimental and therapeutic medicine

Weihan Zhao, Lijuan Liu, Yunliang Wang, Tangyou Mao, Junxiang Li

Affiliations

  1. Gastroenterology Department, Dongfang Hospital, Beijing University of Chinese Medicine, Beijing 100078, P.R. China.

PMID: 26889237 PMCID: PMC4726904 DOI: 10.3892/etm.2015.2846

Abstract

Nonalcoholic fatty liver disease (NAFLD) is a prevalent disease, with a clinical spectrum ranging from simple fatty liver disease to nonalcoholic steatohepatitis and cirrhosis. Puerarin, baicalin and berberine are herbal products widely used in Asia, which are believed to possess therapeutic benefits for alleviating the symptoms of NAFLD. In the present study, a rat model of NAFLD, induced by a high-fat diet, was established and orthographical experimentation was used to investigate the effects of various combinations of puerarin, baicalin and berberine on the hepatic expression of proliferator-activated receptor (PPAR)-γ and insulin receptor (IR). The present study demonstrated that serum levels of total cholesterol, alanine transaminase and low-density lipoproteins were significantly decreased in the puerarin-dominated groups (P<0.05 vs. the model group), whereas the concentrations of tumor necrosis factor-α and interleukin-6 were significantly improved in the baicalin- and berberine-dominated groups (P<0.05 vs. the model group). Furthermore, as compared with the control group, the levels of PPAR-γ/IR mRNA and protein expression were significantly decreased in the model group (P<0.01), and significantly increased in the rosiglitazone group and some of the orthogonal experiment groups (P<0.01). In conclusion, a combination of puerarin, baicalin and berberine induced favorable effects on NAFLD by upregulating hepatic PPAR-γ and IR expression levels, and different proportions of monomer compositions exerted variable positive effects on various stages of NAFLD.

Keywords: baicalin; berberine; insulin receptor; non-alcoholic fatty liver disease; proliferator-activated receptor-γ; puerarin

References

  1. Braz J Med Biol Res. 2014 Sep;47(9):746-52 - PubMed
  2. Hepatology. 2010 Feb;51(2):366-9 - PubMed
  3. J Biol Chem. 1992 Apr 5;267(10):7108-15 - PubMed
  4. J Integr Med. 2014 May;12(3):162-70 - PubMed
  5. Hepatology. 2001 Sep;34(3):595-603 - PubMed
  6. PLoS One. 2014 Sep 11;9(9):e106992 - PubMed
  7. J Lipid Res. 2010 Sep;51(9):2504-15 - PubMed
  8. Am J Chin Med. 2014;42(5):1153-67 - PubMed
  9. Hepatology. 2010 Feb;51(2):679-89 - PubMed
  10. Clin Liver Dis. 2007 Feb;11(1):105-17, ix - PubMed
  11. Scand J Gastroenterol. 2009;44(3):358-65 - PubMed
  12. Genet Mol Res. 2014 Aug 28;13(3):6577-81 - PubMed
  13. J Clin Invest. 2008 Mar;118(3):829-38 - PubMed
  14. Hepatology. 2004 Jan;39(1):188-96 - PubMed
  15. Postgrad Med J. 2006 May;82(967):315-22 - PubMed
  16. J Integr Med. 2014 May;12(3):135-46 - PubMed
  17. Iran J Basic Med Sci. 2014;17(4):263-70 - PubMed
  18. Diabetes Care. 2004 Jan;27(1):256-63 - PubMed
  19. Gastroenterology. 1999 Jun;116(6):1413-9 - PubMed
  20. Adv Ther. 2009 Oct;26(10):893-907 - PubMed
  21. Neural Dev. 2010 Mar 15;5:7 - PubMed
  22. Acta Pharmacol Sin. 2009 Nov;30(11):1505-12 - PubMed
  23. Circulation. 2000 Mar 21;101(11):1311-8 - PubMed
  24. Hepatology. 2007 Aug;46(2):424-9 - PubMed
  25. Ann Intern Med. 2001 Jan 2;134(1):61-71 - PubMed
  26. World J Gastroenterol. 2004 May 1;10(9):1329-32 - PubMed
  27. Chin Med J (Engl). 2012 Jul;125(13):2316-21 - PubMed
  28. J Integr Med. 2013 Jul;11(4):262-8 - PubMed
  29. Gastroenterology. 1998 Apr;114(4):842-5 - PubMed
  30. Exp Ther Med. 2014 Mar;7(3):663-668 - PubMed
  31. Chin Med J (Engl). 2011 Mar;124(6):867-72 - PubMed
  32. Biochem Biophys Res Commun. 1989 Feb 28;159(1):312-6 - PubMed
  33. Methods Mol Biol. 2015;1233:15-23 - PubMed
  34. J Integr Med. 2013 May;11(3):153-6 - PubMed
  35. Clin Transl Sci. 2013 Dec;6(6):481-4 - PubMed
  36. Cell. 2012 Mar 2;148(5):852-71 - PubMed
  37. World J Gastroenterol. 2014 Jul 14;20(26):8364-76 - PubMed

Publication Types